RECRUITING

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Background: \- Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective. Researchers want to collect blood or cheek swab samples from people having cancer treatment to study these genes. Objectives: \- To obtain a blood or cheek swab sample to study genetic differences that may affect cancer treatment. Eligibility: \- Individuals with cancer who are being treated at the National Cancer Institute. Design: * Participants will provide a blood sample for study. * Participants who have blood-based cancer, such as leukemia, will provide a cheek swab sample. * If the blood or cheek swab sample does not have enough genetic material for analysis, an additional sample may be collected.

Official Title

Collection of Blood From Therapeutic Trial Participants for Analysis of Genetic Differences in Drug Disposition and Pharmacokinetics of Probe Medications

Quick Facts

Study Start:2012-05-21
Study Completion:N/A
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT01441089

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:3 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Any individual currently enrolled in an NIH intramural research program clinical trials receiving treatment.
  2. * Ability of participant or Legally Authorized Representative (LAR) to understand and be willing to sign the informed consent document.
  3. * Age \>= 3 years old
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Deneise C Francis, R.N.
CONTACT
(240) 858-3974
deneise.francis@nih.gov
William D Figg, Pharm.D.
CONTACT
(240) 760-6179
figgw@mail.nih.gov

Principal Investigator

William D Figg, Pharm.D.
PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)

Study Locations (Sites)

National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
United States

Collaborators and Investigators

Sponsor: National Cancer Institute (NCI)

  • William D Figg, Pharm.D., PRINCIPAL_INVESTIGATOR, National Cancer Institute (NCI)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2012-05-21
Study Completion DateN/A

Study Record Updates

Study Start Date2012-05-21
Study Completion DateN/A

Terms related to this study

Keywords Provided by Researchers

  • Pharmacogenetics
  • Pharmacokinetics
  • Pharmacodynamics
  • Clinical Outcome
  • Drug Metabolism and Transport
  • Natural History
  • Cancer

Additional Relevant MeSH Terms

  • Prostate Cancer
  • Breast Cancer
  • Lung Cancer
  • Ovarian Cancer
  • Lymphoma